
REVENUE MEMORANDUM CIRCULAR NO. 5-2022 issued on January 17, 2022 publishes the letter from Director General Rolando Enrique D. Domingo of the Food and Drug Administration endorsing the copy of the “Corrigendum to the List of Medicines for Kidney Diseases” pursuant to Section 109(1)(AA) of the Tax Code of 1997, as amended by Republic Act No. 11534, and as implemented under Section 4.109-(1)(B)(aa) of Revenue Regulations No. 4-2021, as amended.
The Circular updates and supplements Revenue Memorandum Circular No. 81-2021, which published the consolidated list of VAT-exempt products and has become the controlling list insofar as the VAT exemption of items under Sections 109(1)(AA) and 109(1)(BB)(ii) of the Tax Code of 1997, as amended, is concerned.